Innovation is the most sought-after goal of executives, and yet it is also one of the most challenging to achieve, with over 90% of new products failing. These high-rates of failure are not from a lack of ideas or energy. It has everything to do with how to frame the problem, and which inputs to use to solve the problem.
As the founder and CEO of the Medicines Company, which was acquired by Novartis for 9.7bn in 2019, Dr. Clive Meanwell understands this problem all too well. He believes that many of our business problems can be solved by a change in mindset.
Instead of thinking solutions and ideas first, you must think of outcomes first.
In this session, we will discuss what led Clive to change his way of thinking, the impact it has had on his organizations, and how he hopes to start a movement to change how the pharmaceutical industry addresses population health outcomes.
Join Strategyn Founder and CEO Tony Ulwick and Dr. Clive Meanwell for this discussion on innovation leadership.
Dr. Clive Meanwell received his MD and PhD from the University of Birmingham in the UK where he also trained in medical oncology. Dr. Meanwell founded The Medicines Company in 1996 until January 6, 2020 when it was sold to Novartis for 9.7bn. He currently sits on the Board of Directors for several organizations and has recently founded the Population Health Investment Group.